MPR3d
Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
Healio4d
CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Zacks.com on MSN2d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
GlobalData on MSN3d
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
Devdiscourse4d
Novo Nordisk's CagriSema: A Breakthrough in Obesity Treatment for Diabetics
Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...